Ameritas Investment Partners Inc. grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,256 shares of the medical research company’s stock after purchasing an additional 291 shares during the period. Ameritas Investment Partners Inc.’s holdings in Charles River Laboratories International were worth $1,442,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Charles River Laboratories International by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock valued at $511,893,000 after purchasing an additional 27,217 shares during the period. BlackRock Inc. boosted its holdings in shares of Charles River Laboratories International by 4.6% in the 2nd quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock worth $406,913,000 after acquiring an additional 177,239 shares in the last quarter. FMR LLC boosted its holdings in shares of Charles River Laboratories International by 23.8% in the 2nd quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after acquiring an additional 591,066 shares in the last quarter. State Street Corp boosted its holdings in shares of Charles River Laboratories International by 2.3% in the 2nd quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock worth $128,288,000 after acquiring an additional 28,365 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Charles River Laboratories International by 14.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,219,883 shares of the medical research company’s stock worth $123,391,000 after acquiring an additional 153,374 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Charles River Laboratories International, Inc. (CRL) traded up 1.25% on Monday, reaching $114.33. The company’s stock had a trading volume of 16,176 shares. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $114.33. The firm’s 50 day moving average is $108.17 and its 200-day moving average is $98.26. The firm has a market cap of $5.44 billion, a P/E ratio of 30.13 and a beta of 0.96.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. The firm had revenue of $469.13 million for the quarter, compared to analysts’ expectations of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.20 earnings per share. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Ameritas Investment Partners Inc. Has $1.44 Million Stake in Charles River Laboratories International, Inc. (CRL)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/ameritas-investment-partners-inc-has-1-44-million-stake-in-charles-river-laboratories-international-inc-crl/1634614.html.

Several research analysts have recently commented on the company. Jefferies Group LLC reissued a “buy” rating and issued a $121.00 target price on shares of Charles River Laboratories International in a report on Friday, June 30th. Credit Suisse Group reissued a “neutral” rating and issued a $112.00 target price (up from $95.00) on shares of Charles River Laboratories International in a report on Monday. Citigroup Inc. reissued a “neutral” rating and issued a $104.00 target price (up from $91.00) on shares of Charles River Laboratories International in a report on Wednesday, June 28th. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 20th. Finally, Barclays PLC reissued a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 19th. Six equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $102.05.

In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total transaction of $678,150.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William D. Barbo sold 4,000 shares of the business’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the sale, the insider now directly owns 20,424 shares in the company, valued at approximately $2,040,561.84. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,699 shares of company stock worth $1,892,393. Insiders own 2.20% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.